Danielle Ternyila

A Breakthrough Therapy designation was granted to plinabulin as treatment of chemotherapy-induced neutropenia from both the FDA in the United States and China’s Center for Drug Evaluation of the National Medical Products Administration.

JAK inhibitors continue to make a splash in the treatment landscape of MPNs and are be evaluated in multiple clinical trials, and the advancement of these agents should be recognized in honor of MPN Awareness Day.

Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.

CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.

In an interview with Targeted Oncology, Alan P. Z. Skarbnik, MD, discussed the current therapeutic strategies for treating patients with FL.

The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.

In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.

A statistically significant overall survival benefit was not observed with osimertinib compared with platinum-pemetrexed therapy as treatment of patients with EGFR T790M-mutated advanced non–small cell lung cancer.

The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.

In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the evolution she has observed in thyroid cancer in terms of the use of targeted therapies and other important milestones for this patient population.

The survival outcomes observed in this study further supported the biosimilarity between bevacizumab and SB8.

RAS status detected in circulating tumor DNA was associated significantly with clinical outcomes when patients with metastatic colorectal cancer were rechallenged with anti-EGFR monoclonal antibody therapy of either cetuximab or panitumumab, according to findings from a clinical study evaluating RAS mutational status in ctDNA using the OncoBEAM RAS CRC test kit in 2 Japanese multicenter, prospective studies.

The FDA granted an Orphan Drug designation to tolinapant for the treatment of patients with T-cell lymphomas.

The FDA granted a Priority Review to the New Drug Application for oral paclitaxel with encequidar for the treatment of patients with metastatic breast cancer.

In an interview with Targeted Oncology, Andrei Gafita, MD, discussed the recent findings from the international multicenter retrospective analysis of LuPSMA as treatment of patients with metastatic castration-resistant prostate cancer, and how these findings and more clinical trials could lead to the approval of this treatment for patients who have exhausted all other standard treatments.

The FDA granted a Fast Track and Orphan Drug designation to VLS-101 for the treatment of patients with mantle cell lymphoma.

The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.

Targeted Oncology reviews trending news online for the week of August 28, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

This is the first report to date that has demonstrated inferior survival outcomes among African American patients with NSCLC harboring an EGFR mutation relative to non-African American patients.

The FDA has granted approval to FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for all solid tumors with multiple companion diagnostic indications.

Frontline trastuzumab plus lapatinib and an aromatase inhibitor demonstrated superior progression-free survival compared with the trastuzumab/aromatase inhibitor alone as treatment of patients with HER2-positive, HR-positive metastatic breast cancer.

Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they received prior vandetanib or cabozantinib in the phase 1/2 LIBRETTO-001 study.

In an interview with Targeted Oncology, Mehmet Akce, MD, discussed the treatment options available for patients with advanced hepatocellular carcinoma and how he would go about sequencing these treatments in his practice.

The primary end point of statistically superiority in major molecular response rate at 24 weeks was met with asciminib versus bosutinib as treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the phase 3 ASCEMBL study.

In an interview with Targeted Oncology, Marco Mielcarek, MD, PhD, discussed how COVID-19 has impacted the treatment of patients with blood cancers in Washington State.

Overall survival was not improvement with the combination of enasidenib and best supportive care compared with conventional care regimens when administered to patients relapsed/refractory IDH2-positive acute myeloid leukemia.

The FDA granted a Fast Track designation to repotrectinib for the treatment of patients with advanced solid tumors that have an NTRK gene fusion and have progressed on at least 1 prior line of chemotherapy and 1 to 2 prior TRK tyrosine kinase inhibitors, leaving them with no satisfactory alternative treatment options.

A single-center experience demonstrated that certain pre- and post-treatment characteristics may predict outcomes for patients with diffuse large B-cell lymphoma following treatment with a chimeric antigen receptor T-cell therapy.

In an interview with Targeted Oncology, Philip A. Philip, MD, PhD, discussed the current therapeutic options for patients with metastatic pancreatic cancer and where CPI-613 may fit into this treatment landscape.